Grifols, S.A. (GIKLY)
USD 5.13
(0.0%)
USD 5.13
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 9.58 Billion EUR | 4.19% |
| 2022 | 9.2 Billion EUR | 6.15% |
| 2021 | 8.66 Billion EUR | 36.91% |
| 2020 | 6.33 Billion EUR | -0.52% |
| 2019 | 6.36 Billion EUR | 21.12% |
| 2018 | 5.25 Billion EUR | 2.54% |
| 2017 | 5.12 Billion EUR | 28.44% |
| 2016 | 3.99 Billion EUR | 10.34% |
| 2015 | 3.61 Billion EUR | 14.5% |
| 2014 | 3.15 Billion EUR | 59.46% |
| 2013 | 1.98 Billion EUR | -14.06% |
| 2012 | 2.3 Billion EUR | -11.92% |
| 2011 | 2.61 Billion EUR | 323.8% |
| 2010 | 617.37 Million EUR | 8.73% |
| 2009 | 567.8 Million EUR | 20.96% |
| 2008 | 469.39 Million EUR | 27.63% |
| 2007 | 367.79 Million EUR | 18.52% |
| 2006 | 310.32 Million EUR | 14.61% |
| 2005 | 270.77 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 10.94 Billion EUR | 14.18% |
| 2024 Q2 | 8.52 Billion EUR | -22.1% |
| 2023 Q4 | 9.58 Billion EUR | -9.31% |
| 2023 Q3 | 10.57 Billion EUR | 1.54% |
| 2023 Q1 | 10.33 Billion USD | 12.3% |
| 2023 Q2 | 10.41 Billion EUR | 0.76% |
| 2023 FY | 9.58 Billion EUR | 4.19% |
| 2022 Q4 | 9.2 Billion USD | 1779.29% |
| 2022 FY | 9.2 Billion EUR | 6.15% |
| 2022 Q2 | 9.03 Billion EUR | 236.34% |
| 2022 Q3 | -547.97 Million EUR | -106.07% |
| 2022 Q1 | 2.68 Billion EUR | -71.62% |
| 2021 Q1 | 6.98 Billion EUR | 10.35% |
| 2021 Q2 | 7.2 Billion EUR | 3.16% |
| 2021 Q3 | 9.46 Billion EUR | 31.27% |
| 2021 FY | 8.66 Billion EUR | 36.91% |
| 2021 Q4 | 9.46 Billion USD | 0.0% |
| 2020 FY | 6.33 Billion EUR | -0.52% |
| 2020 Q4 | 6.33 Billion EUR | 5.27% |
| 2020 Q3 | 6.01 Billion EUR | -2.43% |
| 2020 Q2 | 6.16 Billion EUR | -5.99% |
| 2020 Q1 | 6.55 Billion EUR | 3.02% |
| 2019 Q4 | 6.36 Billion EUR | -2.48% |
| 2019 FY | 6.36 Billion EUR | 21.12% |
| 2019 Q1 | -246.74 Million EUR | -104.7% |
| 2019 Q2 | 6.43 Billion EUR | 2708.76% |
| 2019 Q3 | 6.52 Billion EUR | 1.4% |
| 2018 Q1 | -672.11 Million EUR | -113.12% |
| 2018 FY | 5.25 Billion EUR | 2.54% |
| 2018 Q4 | 5.25 Billion EUR | -9.11% |
| 2018 Q3 | 5.78 Billion EUR | 5.5% |
| 2018 Q2 | 5.48 Billion EUR | 915.34% |
| 2017 Q4 | 5.12 Billion EUR | 895.08% |
| 2017 Q2 | 5.39 Billion EUR | 1033.27% |
| 2017 FY | 5.12 Billion EUR | 28.44% |
| 2017 Q1 | -578.47 Million EUR | -114.5% |
| 2017 Q3 | -644.55 Million EUR | -111.94% |
| 2016 Q4 | 3.99 Billion EUR | 6.17% |
| 2016 Q2 | 3.86 Billion EUR | 8.14% |
| 2016 FY | 3.99 Billion EUR | 10.34% |
| 2016 Q1 | 3.57 Billion EUR | -1.13% |
| 2016 Q3 | 3.75 Billion EUR | -2.8% |
| 2015 FY | 3.61 Billion EUR | 14.5% |
| 2015 Q4 | 3.61 Billion EUR | -1.53% |
| 2015 Q3 | 3.67 Billion EUR | -2.22% |
| 2015 Q2 | 3.75 Billion EUR | -4.18% |
| 2015 Q1 | 3.91 Billion EUR | 24.11% |
| 2014 Q3 | 3.2 Billion EUR | 3.02% |
| 2014 Q2 | 3.1 Billion EUR | -0.51% |
| 2014 FY | 3.15 Billion EUR | 59.46% |
| 2014 Q1 | 3.12 Billion EUR | 57.78% |
| 2014 Q4 | 3.15 Billion EUR | -1.4% |
| 2013 Q1 | 2.42 Billion EUR | 5.04% |
| 2013 Q2 | 2.33 Billion EUR | -3.69% |
| 2013 FY | 1.98 Billion EUR | -14.06% |
| 2013 Q3 | 2.23 Billion EUR | -3.99% |
| 2013 Q4 | 1.98 Billion EUR | -11.52% |
| 2012 Q1 | 2.58 Billion EUR | -1.26% |
| 2012 Q4 | 2.3 Billion EUR | -4.8% |
| 2012 Q3 | 2.42 Billion EUR | -6.74% |
| 2012 FY | 2.3 Billion EUR | -11.92% |
| 2012 Q2 | 2.59 Billion EUR | 0.48% |
| 2011 Q4 | 2.61 Billion EUR | -6.47% |
| 2011 Q2 | 2.56 Billion EUR | 0.0% |
| 2011 FY | 2.61 Billion EUR | 323.8% |
| 2011 Q3 | 2.79 Billion EUR | 8.89% |
| 2010 Q4 | 617.37 Million EUR | 0.0% |
| 2010 FY | 617.37 Million EUR | 8.73% |
| 2009 FY | 567.8 Million EUR | 20.96% |
| 2008 FY | 469.39 Million EUR | 27.63% |
| 2007 FY | 367.79 Million EUR | 18.52% |
| 2006 FY | 310.32 Million EUR | 14.61% |
| 2005 FY | 270.77 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 57.855% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 68.04% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 701.482% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | -60375.981% |
| Novartis AG | 12.95 Billion USD | 25.991% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 5749.837% |